SCHEMBL7188910

SCHEMBL7188910

Cc1c(C)c(C)c(C(=O)c2ccccc2[P](=O)C(=O)c2c(Cl)cccc2Cl)c(C)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
GAA P10253 1/20 0.44
CNR2 P34972 2/20 0.39
RORC P51449 7/20 0.37
CYP2C9 P11712 3/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C19 P33261 2/20 0.37
USP2 O75604 1/20 0.37
MT-CO2 P00403 1/20 0.37
TTR P02766 1/20 0.37
PLA2G1B P04054 1/20 0.37
PGR P06401 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
AR P10275 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188870 0.91 LMNA (0.41) ALDH1A1LMNAGAACNR2RORC
SCHEMBL7179797 0.89 RORC (0.42) ALDH1A1LMNAGAACNR2RORC
SCHEMBL7175611 0.89 LMNA (0.40) ALDH1A1LMNAGAACNR2RORC
SCHEMBL7181167 0.88 LMNA (0.41) ALDH1A1LMNAGAACNR2RORC
SCHEMBL7174823 0.86 RORC (0.42) ALDH1A1LMNAGAACNR2RORC
SCHEMBL7177230 0.86 LMNA (0.40) ALDH1A1LMNAGAACNR2RORC
SCHEMBL7181446 0.86 GFER (0.36) ALDH1A1LMNAGAACNR2RORC
SCHEMBL7179370 0.86 TSHR (0.38) ALDH1A1LMNAGAACNR2RORC
SCHEMBL7190480 0.85 MEN1 (0.47) ALDH1A1LMNAGAACNR2RORC
SCHEMBL7189834 0.84 TSHR (0.40) ALDH1A1LMNAGAACNR2RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ALDH1A1 3416/4885LMNA 3241/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885LMNA 3247/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.